BioSpace News Archive

Acceptance marks critical milestone in Biohaven’s efforts to develop NURTEC ODT as a unique dual therapy for both the preventive and acute treatment of migraine NURTEC ODT 75 mg has been shown in placebo-controlled trials to return patients to normal functioning within 60 minutes when used in the acute treatment of migraine and has also been shown to reduce monthly migraine days at the same 75 mg dose administered every other day for preventive treatment

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has received the prestigious C. Everett Koop National Health Award for 2020. Named for C. Everett Koop , the 13th Surgeon General of the United States (1982-1989), the

Healthcare industry’s most trusted drug database to drive streamlined inpatient pharmacy workflows for hospitals using CliniComp’s EHR

MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it is exploring the pharmacological effect of EscharEx®

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary financial results for the quarter ended September 30, 2020.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced plans to develop two new sterile filling lines in Singapore to extend capacity to the Asia-Pacific region for the development a

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), today announced its recently acquired SciSafe division has been awarded a two year contract from a large pharmaceutical company for cold chain management and storage of COVID-19 vaccines.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced it has signed an agreement with FASMAC Co., Ltd of Japan.

Bioavailability enhancer is an agent that is combined with a drug to increase the bioefficacy and bioavailability of the drug.

In simple words, apoptosis assays refers to programmed cell deaths, which are able to regulate genetically cell ablation over the period of normal development.